Gilead Sciences
The Senior Manager, Medical Information at Gilead provides strategic and scientific leadership for the development and delivery of high-quality medical information for the company's products. Serving as a Therapeutic Area subject matter expert, this role leads the creation of complex medical responses, partners cross-functionally to develop global content, and ensures compliance with regulatory standards. The position involves analyzing customer insights to inform content strategy, supporting product launches, and potentially providing oversight or people leadership to advance medical information and patient care.
Headquarters
Foster City, California, United States
Company Size
10001+ employees
Founded
1987
Gilead Sciences is a biopharmaceutical company dedicated to transforming patient care by advancing therapeutics in areas like HIV, liver disease, cancer, and inflammation. With a strong commitment to innovation, Gilead leads in the research and development of new medicines, aiming to make the world a healthier place. Their portfolio includes breakthrough therapies and ongoing advancements across multiple therapeutic areas, supported by a robust pipeline of clinical trials. Gilead is recognized for its contributions to public health and its efforts to improve access to vital medications.
Franklin Resources Inc. Decreases Stake in Gilead Sciences, Inc. $GILD
4 hours ago
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Momentum And Mixed Fair Value Signals
1 hour ago
Jefferies initiates Gilead Sciences stock with buy rating
2 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Gilead Sciences.
5% below the average for this role
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained
2 days ago